GOSS Gossamer Bio, Inc. Common Stock
XNAS
0.40
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
GOSS
$0.40
—
Key stats
$0.40
- 52-Week Range
- $8.29 – $309.60
- YTD
- -99.83%
- Straddle Price
- $0.55
- P/C Vol Ratio
- 0.00
- Market Cap
- $0.1B
- Open
- $9.73
- Day Range
- $9.56 – $9.96
- Volume
- 125,695
- Prev Close
- $9.79
Fair Value
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 1.39 |
| Cost of Equity (CAPM) | 12.79% (VRP-adj) |
| WACC | 5.27% |
| Volatility Risk Premium | +735.2pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.2B |
| Return on Equity (TTM) | 133.2% |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -292.8% |
| Quality Score | 3/6 — normal (10y DCF) |
| SMA 50 | $11.63 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $10.13 |
| Bollinger Width / SMA20 | 387.1% (drives anchor stability) |
| Net Debt | $0.2B |
Peers used for multiples: AMGN, AXSM, GILD, MRNA, PTGX, REGN, RVMD, VRTX
Blended Fair Value
—
Deviation
—
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 28.4× · 4 peers |
| Peer EV/EBITDA | n/a | 0% | median 24.2× · 5 peers |
| Peer P/B | n/a | 0% | median 15.2× · 8 peers |
| Peer P/S | n/a | 0% | median 10.4× · 7 peers |
| Market Anchor (SMA50) | $11.63 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.1B
- Employees
- 162
- List Date
- 2019-02-08
- CIK
- 0001728117
- Next Earnings
- 2026-11-04 (After-Close)
- EPS Forecast
- ($5.55) (3 est.)
- Headquarters
- San Diego, CA
- Homepage
- https://www.gossamerbio.com
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 0.30% | -19.34% | 29.41% | -13.40% | 2.43% | -20.83% | -3.57% |
| Feb | -7.02% | -4.95% | -38.87% | 70.08% | 19.42% | -82.87% | -7.37% |
| Mar | -6.94% | -4.30% | -24.10% | -14.49% | -6.78% | -23.36% | -13.33% |
| Apr | -7.59% | -23.22% | 15.18% | -44.09% | 2.58% | 0.77% | -9.40% |
| May | -2.64% | -1.26% | 1.52% | -16.61% | 4.72% | -37.56% | -8.64% |
| Jun | -5.36% | 20.95% | -2.44% | 55.19% | 6.49% | -16.91% | 9.65% |
| Jul | -6.32% | 34.33% | 2.27% | -4.67% | 63.20% | 1.07% | 14.98% |
| Aug | 29.60% | 24.89% | -25.18% | -0.25% | 23.50% | -2.07% | 8.42% |
| Sep | 22.28% | -17.83% | -20.69% | 13.73% | 1.54% | -11.51% | -2.08% |
| Oct | -4.83% | -4.80% | -34.93% | -16.38% | -1.61% | -9.79%* | -12.06% |
| Nov | -15.05% | -21.11% | 62.96% | -20.10% | 39.75% | -- | 9.29% |
| Dec | 4.72% | -73.70% | 7.86% | 23.95% | -1.27% | -- | -7.69% |
| Total | -7.12% | -81.68% | -52.46% | -18.38% | 262.40% | -95.71% | 1.18% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $10.08
SMA 50: $11.54
SMA 200: $46.93
Current: $9.86
EMA 12: $9.62
EMA 26: $10.29
MACD: -0.6682 | Signal: 0.0844
BEARISH
ADX (14): 16.24
RANGE
+DI: 21.59
−DI: 22.19
Momentum Oscillators
RSI (14): 45.72
NEUTRAL
Stoch %K: 47.82
Stoch %D: 30.51
Williams %R: -41.76
Volume & Volatility
BB Upper: $12.04
BB Lower: $8.12
NEUTRAL
OBV: -3,785,944
Vol SMA 20: 288,060
Vol ROC: -36.33%
ATR: $0.95
True Range: $0.40
HV 20: 79.0%
HV 30: 83.8%
HV 60: 99.5%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
LLM Stock Analysis Report: GOSS
Executive Summary
Overall Assessment: BEARISH (Confidence Level: 6/10)
Key Drivers:
- Bearish MACD signal
- Neutral RSI reading, but high volatility
- Negative news sentiment impact
Primary Risks:
- High volatility and potential for further price swings
- Downtrend momentum could continue if bearish momentum persists
Investment Thesis: GOSS is likely to experience continued volatility and potentially decline in the short-term due to bearish technical signals. However, the options market suggests a possible mean reversion towards $2.55 by expiration.
Recent News Sentiment Impact: None available due to lack of recent news headlines.
Technical Analysis
Trend Direction: Short-term: BEARISH (1-4 weeks), Medium-term: NEUTRAL (1-3 months), Long-term: BEARISH (3-12 months)
Support/Resistance Levels:
- Upper Bollinger Band: $2.75
- Middle Bollinger Band: $2.38
- Lower Bollinger Band: $2.02
Momentum Signals:
- RSI: 36.16 (neutral)
- MACD: -0.16 / Signal: -0.01 / Histogram: -0.15 (bearish)
News & Sentiment Analysis
Recent Headlines Summary: None available due to lack of recent news headlines.
Sentiment Assessment: Neutral due to absence of recent news sentiment.
Catalyst Identification: Earnings date on 2025-08-05 could provide a market-moving event.
Market Narrative: The bearish MACD signal and high volatility suggest potential for further price swings, while the options market suggests a possible mean reversion towards $2.55 by expiration.
Risk & Volatility Assessment
Beta Interpretation: Beta: 1.43 (vs SPY) - High risk relative to the broader market.
Volatility Regime: Current volatility is high compared to historical levels.
Options Market Signals:
- IV Rank: 93.7% (High)
- Put/Call Volume Ratio: 0.55 (Bullish sentiment)
- Put/Call OI Ratio: 0.93
Market Context & Positioning
Sector Performance: GOSS is relatively weak compared to its sector peers.
Institutional Activity: Institutional interest is moderate, as seen in the volume flow and open interest ratios.
Correlation Analysis: GOSS has a high correlation with the broader market (R-squared: 0.31).
Relative Valuation: GOSS is currently trading near the lower end of its historical range.
Key Levels & Action Items
Critical Price Levels:
- Lower Bollinger Band: $2.02
- Middle Bollinger Band: $2.38
Breakout/Breakdown Levels: Upper Bollinger Band: $2.75 (potential resistance)
Time-Sensitive Catalysts: Earnings date on 2025-08-05
Risk Management: Consider using stop-loss levels at the Lower Bollinger Band ($2.02) and position sizing to manage potential risk.
Please note that this analysis is based on the provided data, and you should always consider other factors before making any investment decisions.
Generated
News
All GOSS news →
Earnings History
20 of 20 under expected move
Avg Expected Move
76.20%
Avg Actual Move
7.30%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-25 | After-Close | 20.43% | 3.98% | 0.19x | Within |
| 2021-08-09 | After-Close | 7.18% | 2.15% | 0.30x | Within |
| 2021-11-08 | After-Close | 14.61% | 1.87% | 0.13x | Within |
| 2022-04-25 | After-Close | 17.62% | 15.53% | 0.88x | Within |
| 2022-08-09 | After-Close | 14.11% | 5.01% | 0.36x | Within |
| 2022-11-03 | After-Close | 13.68% | 0.75% | 0.05x | Within |
| 2023-03-17 | After-Close | 27.05% | 25.90% | 0.96x | Within |
| 2023-05-09 | After-Close | 20.29% | 3.68% | 0.18x | Within |
| 2023-08-08 | After-Close | 24.80% | 1.64% | 0.07x | Within |
| 2024-03-05 | After-Close | 19.31% | 4.14% | 0.21x | Within |
| 2024-05-07 | After-Close | 20.45% | 3.27% | 0.16x | Within |
| 2024-08-12 | After-Close | 20.61% | 3.81% | 0.18x | Within |
| 2024-11-07 | After-Close | 14.53% | 0.91% | 0.06x | Within |
| 2025-03-13 | After-Close | 817.46% | 11.54% | 0.01x | Within |
| 2025-05-15 | After-Close | 24.15% | 0.95% | 0.04x | Within |
| 2025-08-05 | Pre-Market | 11.52% | 0.46% | 0.04x | Within |
| 2025-11-05 | After-Close | 20.04% | 2.53% | 0.13x | Within |
| 2026-03-17 | After-Close | 110.56% | 7.99% | 0.07x | Within |
| 2026-05-18 | After-Close | 155.68% | 3.32% | 0.02x | Within |
| 2026-07-27 | Pre-Market | 150.00% | 46.62% | 0.31x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
GOSS Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $0.55
7-DTE Move: $0.55
Days to Exp: 29 (2026-11-20)
Options Flow
Call Volume: 11
Put Volume: 0
P/C Volume: —
BULLISH
Call OI: 2,424
Put OI: 211
P/C OI: 0.087
Total OI: 2,635
ATM Options Pricing
ATM Call: $0.03
ATM Put: $0.53
Call %: 6.3%
Put %: 131.3%
Chain Summary
Chain Volume: 309
Chain OI: 66,421
Last Updated: 10/22/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 20th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
20%
vs own history
GEX tilt
-0.74
OI-weighted, today
Vanna tilt
-0.50
δ-sensitivity to IV
Charm tilt
+0.78
δ-decay vs time
Vanna tilt -0.50: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt +0.78: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 3 ATM contracts, 3k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
ATM 1575.0% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$0.55Oct 22
Beta Analysis
Risk Metrics
Beta: 2.1573
Alpha: -169.80%
Correlation: 0.1953
R-Squared: 3.8%
Stock Volatility: 141.1%
Market Volatility: 12.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own GOSS
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $1.9M | #1973 of 3138 | +854.9% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $395K | #3259 of 3716 | +1182.0% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $17K | #3777 of 4729 | -1.6% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
GOSS Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 229,478,358 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
5 filers$515.41K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Wolverine Trading, LLC Custodian | $278.05K | 53.95% | 2025-09-30 |
| 2 | Susquehanna International Group, LLP Custodian | $187.49K | 36.38% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $25.78K | 5.00% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $22.22K | 4.31% | 2026-06-30 |
| 5 | Volterra Technologies LP | $1.88K | 0.36% | 2026-06-30 |
2 filers$17.94K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $12.18K | 67.89% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $5.76K | 32.11% | 2026-06-30 |
GOSS Insider Trading (Form 4)
Latest: 2026-09-25Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-25 | Gregory Austin Ciongoli | Director | Grant (A) | +30,000 opt | — | EDGAR | |
| 2026-09-25 | Skye Drynan | Director | Grant (A) | +10,000 opt | — | EDGAR | |
| 2026-09-25 | Thomas O Daniel | Director | Grant (A) | +10,000 opt | — | EDGAR | |
| 2026-09-25 | Sandra Milligan | Director | Grant (A) | +10,000 opt | — | EDGAR | |
| 2026-09-25 | Steven D Nathan | Director | Grant (A) | +10,000 opt | — | EDGAR | |
| 2026-09-25 | Russell J. Cox | Director | Grant (A) | +10,000 opt | — | EDGAR | |
| 2026-09-25 | John D Quisel | Director | Grant (A) | +10,000 opt | — | EDGAR | |
| 2026-08-26 | Robert Paul Smith JR | Chief Commercial Officer | Grant (A) | +5,800,051 opt | — | EDGAR | |
| 2026-08-26 | Bryan Giraudo | COO/CFO | Grant (A) | +5,800,076 opt | — | EDGAR | |
| 2026-08-26 | Waage Christian | EVP, Tech Ops and Admin | Grant (A) | +2,900,026 opt | — | EDGAR | |
| 2026-08-26 | Caryn Peterson | Chief Development Officer | Grant (A) | +5,800,051 opt | — | EDGAR | |
| 2026-08-26 | Faheem Hasnain | President & CEO | Grant (A) | +5,800,217 opt | — | EDGAR | |
| 2026-06-05 | Steven D Nathan | Director | Grant (A) | +115,000 opt | — | EDGAR | |
| 2026-06-05 | Sandra Milligan | Director | Grant (A) | +115,000 opt | — | EDGAR | |
| 2026-06-05 | Russell J. Cox | Director | Grant (A) | +115,000 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
GOSS Insider Holdings
9 insiders · @ $9.86
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Faheem Hasnain | President & CEO | 78,073 | $769.8K | $3.22M | 22 | 2026-08-26 |
| 2 | Bryan Giraudo | COO/CFO | 10,872 | $107.2K | $410.9K | 28 | 2026-08-26 |
| 3 | Waage Christian | EVP, Tech Ops and Admin | 10,750 | $106.0K | -$17.7K | 22 | 2026-08-26 |
| 4 | Richard Aranda | Chief Medical Officer | 5,821 | $57.4K | -$168.0K | 19 | 2026-03-20 |
| 5 | Robert Paul Smith JR | Chief Commercial Officer | 3,573 | $35.2K | $15.1K | 7 | 2026-08-26 |
| 6 | Caryn Peterson | Chief Development Officer | 3,242 | $32.0K | -$152.2K | 17 | 2026-08-26 |
| 7 | Sandra Milligan | Director | 1,126 | $11.1K | $75.2K | 9 | 2026-09-25 |
| 8 | Thomas O Daniel | Director | 476 | $4.7K | $0 | 10 | 2026-09-25 |
| 9 | Russell J. Cox | Director | 90 | $887 | $115.2K | 10 | 2026-09-25 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
GOSS Board & Officers
As of SEC filings through Sep 25, 2026Directors 8
- Faheem Hasnain · since Feb 7, 2019
- Russell J. Cox · since Feb 7, 2019
- Thomas O Daniel · since Feb 7, 2019
- Sandra Milligan · since Jun 10, 2021
- John D Quisel · since Nov 28, 2023
- Skye Drynan · since Mar 11, 2024
- Steven D Nathan · since Mar 11, 2024
- Gregory Austin Ciongoli · since Sep 16, 2026
Officers 6
- Faheem Hasnain · President & CEO · listed since Mar 2021
- Bryan Giraudo · Coo/cfo · listed since Sep 2021
- Richard Aranda · Chief Medical Officer · since Jun 21, 2021
- Robert Paul Smith JR · Chief Commercial Officer · since Dec 4, 2023
- Caryn Peterson · EVP, Regulatory Affairs · since Apr 16, 2021
- Waage Christian · EVP, Tech Ops and Admin · listed since Mar 2022
Changes in the last 10 years (43)
| Sep 16, 2026 | Gregory Austin Ciongoli became a director |
| Mar 11, 2024 | Steven D Nathan became a director |
| Mar 11, 2024 | Skye Drynan became a director |
| Dec 4, 2023 | Robert Paul Smith JR became Chief Commercial Officer |
| Nov 28, 2023 | John D Quisel became a director |
| Sep 6, 2023 | The company announced the departure of Kristina Burow from the board in an SEC filing |
| Mar 24, 2022 | Waage Christian listed as EVP, Tech Ops and Admin (previously EVP & General Counsel) in SEC filings |
| Sep 20, 2021 | Bryan Giraudo listed as Coo/cfo (previously Chief Financial Officer) in SEC filings |
| Jun 21, 2021 | Richard Aranda became Chief Medical Officer |
| Jun 10, 2021 | Sandra Milligan became a director |
| May 3, 2021 | Laura Carter became Chief Scientific Officer |
| Apr 16, 2021 | Caryn Peterson became EVP, Regulatory Affairs |
| Mar 1, 2021 | Faheem Hasnain first listed as President & CEO in an SEC filing |
| Sep 27, 2019 | Faheem Hasnain no longer listed as Executive Chairman in SEC filings |
| Sep 23, 2019 | Omega Fund V, L.P. reported in an SEC filing no longer being a 10% owner |
| Sep 23, 2019 | Omega Fund V GP, L.P. reported in an SEC filing no longer being a 10% owner |
| Sep 23, 2019 | Omega Fund V GP Manager, Ltd. reported in an SEC filing no longer being a 10% owner |
| Feb 7, 2019 | Waage Christian became EVP & General Counsel |
| Feb 7, 2019 | Thomas O Daniel became a director |
| Feb 7, 2019 | Sheila Gujrathi became a director |
| Feb 7, 2019 | Sheila Gujrathi became President & CEO |
| Feb 7, 2019 | Russell J. Cox became a director |
| Feb 7, 2019 | Robert Nelsen became a 10% owner |
| Feb 7, 2019 | Renee D Gala became a director |
| Feb 7, 2019 | Otello Stampacchia became a director |
| Feb 7, 2019 | Otello Stampacchia became a 10% owner |
| Feb 7, 2019 | Omega Fund V, L.P. became a 10% owner |
| Feb 7, 2019 | Omega Fund V GP, L.P. became a 10% owner |
| Feb 7, 2019 | Omega Fund V GP Manager, Ltd. became a 10% owner |
| Feb 7, 2019 | Luisa Salter-Cid became Chief Scientific Officer |
| Feb 7, 2019 | Kristina Burow became a director |
| Feb 7, 2019 | Keith Crandell became a 10% owner |
| Feb 7, 2019 | Joshua H. Bilenker became a director |
| Feb 7, 2019 | Jakob Dupont became Chief Medical Officer |
| Feb 7, 2019 | Faheem Hasnain became a director |
| Feb 7, 2019 | Faheem Hasnain became Executive Chairman |
| Feb 7, 2019 | Clinton Bybee became a 10% owner |
| Feb 7, 2019 | Bryan Giraudo became Chief Financial Officer |
| Feb 7, 2019 | ARCH Venture Partners IX, LLC became a 10% owner |
| Feb 7, 2019 | ARCH Venture Partners IX, L.P. became a 10% owner |
| Feb 7, 2019 | ARCH Venture Partners IX Overage, L.P. became a 10% owner |
| Feb 7, 2019 | ARCH Venture Fund IX, L.P. became a 10% owner |
| Feb 7, 2019 | ARCH Venture Fund IX Overage, L.P. became a 10% owner |
Not reported recently (15)
- Renee D Gala · Last reported as a director in an SEC filing dated Jun 9, 2023
- Laura Carter · Last reported as Chief Scientific Officer in an SEC filing dated Mar 22, 2023
- Joshua H. Bilenker · Last reported as a director in an SEC filing dated Jul 15, 2022
- Luisa Salter-Cid · Last reported as Chief Scientific Officer in an SEC filing dated Mar 25, 2021
- Jakob Dupont · Last reported as Chief Medical Officer in an SEC filing dated Feb 19, 2020
- Sheila Gujrathi · Last reported as a director in an SEC filing dated Feb 19, 2020
- Otello Stampacchia · Last reported as a director in an SEC filing dated Sep 12, 2019
- ARCH Venture Partners IX, L.P. · Last reported as a 10% owner in an SEC filing dated Feb 12, 2019
- ARCH Venture Partners IX, LLC · Last reported as a 10% owner in an SEC filing dated Feb 12, 2019
- ARCH Venture Partners IX Overage, L.P. · Last reported as a 10% owner in an SEC filing dated Feb 12, 2019
- ARCH Venture Fund IX Overage, L.P. · Last reported as a 10% owner in an SEC filing dated Feb 12, 2019
- Robert Nelsen · Last reported as a 10% owner in an SEC filing dated Feb 12, 2019
- Keith Crandell · Last reported as a 10% owner in an SEC filing dated Feb 12, 2019
- ARCH Venture Fund IX, L.P. · Last reported as a 10% owner in an SEC filing dated Feb 12, 2019
- Clinton Bybee · Last reported as a 10% owner in an SEC filing dated Feb 12, 2019
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
11 ETFs hold GOSS
11 shown · $2.87M total exposure · 0.00% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $1.0M | — | 2026-09-30 |
| 2 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $857,122 | — | 2026-09-30 |
| 3 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.00% | $412,151 | $11.0B | 2026-10-20 |
| 4 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.00% | $227,858 | — | 2026-05-31 |
| 5 | VHT Vanguard Health Care ETF | Vanguard | 0.00% | $195,525 | — | 2026-09-30 |
| 6 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.00% | $94,309 | — | 2026-07-31 |
| 7 | ESSC Eventide Small Cap ETF | Nport | 0.10% | $34,671 | — | 2026-07-31 |
| 8 | OMFS Invesco Russell 2000 Dynamic Multifactor ETF | Nport | 0.00% | $13,190 | — | 2026-05-31 |
| 9 | IBBQ Invesco Nasdaq Biotechnology ETF | Nport | 0.00% | $2,819 | — | 2026-05-31 |
| 10 | BIB ProShares Ultra NASDAQ Biotechnology | ProShares | 0.00% | $2,301 | — | 2026-10-21 |
| 11 | MSSM Morgan Stanley Pathway Small-Mid Cap Equity ETF | Nport | 0.00% | $1,668 | — | 2026-05-31 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.79
TTM Revenue
$55.54M
TTM Net Income
$-180.40M
TTM Op. Cash Flow
$-170.26M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | $16.95M | $-46.66M | $-0.20 | $-38.72M |
| Q4 '25 | 2025-12-31 | $13.80M | $-47.24M | $-0.21 | $-48.31M |
| Q3 '25 | 2025-09-30 | $13.29M | $-48.22M | $-0.21 | $-36.17M |
| Q2 '25 | 2025-06-30 | $11.49M | $-38.27M | $-0.17 | $-47.06M |
| Q1 '25 | 2025-03-31 | $9.89M | $-36.64M | $-0.16 | $-39.72M |
| Q4 '24 | 2024-12-31 | $9.38M | $-33.03M | $-0.15 | $-35.48M |
| Q3 '24 | 2024-09-30 | $9.48M | $-30.80M | $-0.14 | $-32.03M |
| Q2 '24 | 2024-06-30 | $95.84M | $49.23M | $0.22 | $116.35M |
| Q1 '24 | 2024-03-31 | — | $-41.93M | $-0.19 | $-52.30M |
| Q4 '23 | 2023-12-31 | — | $-48.15M | $-0.15 | $-33.42M |
| Q3 '23 | 2023-09-30 | — | $-40.01M | $-0.21 | $-34.49M |
| Q2 '23 | 2023-06-30 | — | $-42.50M | $-0.45 | $-38.25M |
Q1 2026 • period ending 2026-03-31 • filed 2026-05-15
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
—
P/S
40.74
EV/EBITDA
—
EV/Sales
43.58
ROE
—
ROA
-140.0%
Div Yield
0.00%
FCF Yield
-7.52%
Debt/Equity
—
Current Ratio
—
Market Cap
$2.26B
as of 2026-10-22
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
1.24M
SI % of Float
21.46%
Days to Cover
3.50
Short Vol Ratio
52.2%
Free Float
5.77M
Float %
94.3%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-09-14